Crowdonomics
All companies
Stark Therapeutics logo

Stark Therapeutics

Operating

Stark Therapeutics Corp

Founded 2018

Visit website

Stark Tx is changing the way the world treats chronic diseases with gene therapy

Valuation cap ⓘ
$8.0M
As of Apr 2021 · from Stark Therapeutics SAFE 1 · a SAFE/note conversion ceiling, not a priced valuation
Total raised
$25,982
Across 1 round since 2020

Financials

FY2018–FY2019 · from SEC filings · hover any figure for its source
$0
2018
$0
2019
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2018
FY2019
Income statement
Revenue
$0
$0
Cost of goods sold
$0
$0
Net income
$0
$0
Taxes paid
$450
$450
Balance sheet
Cash
$0
$0
Accounts receivable
$0
$0
Total assets
$0
$0
Short-term debt
$0
$0
Long-term debt
$0
$0
Total liabilities
$0
$0
Other
Headcount
—
1

Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited; no pill means the filing didn’t state one. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.

Valuation over rounds

Post-money = pre-money + amount raised · caps marked
$8.0M
Valuation cap
Stark Therapeutics SAFE 1

A dashed amber step is a SAFE/note valuation cap — a conversion ceiling agreed for that instrument, not a priced valuation of the company. Steps are not comparable across bases.

Fundraising history

Stark Therapeutics SAFE 1ClosedReg CF · SAFE · via WeFunder
Raised $26K / $1.1MValuation cap $8M

Team

1 person
Anthony Stark
CEO & CTO

Names and titles as disclosed on SEC Form C. Bios and photos come from the platform campaign page and may be out of date.

Reg CF annual-report compliance

Delinquent

Filed 0 of 6 annual reports (FY2020–FY2025)

Missing: 2020, 2021, 2022, 2023, 2024, 2025

Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.

SEC filings

  • Form CJul 24, 20200001670254-20-000652
    EDGAR
Source: ManualCIK 0001818965

About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.